896 related articles for article (PubMed ID: 16704199)
1. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.
Basu A; Yang K; Wang M; Liu S; Chintala R; Palm T; Zhao H; Peng P; Wu D; Zhang Z; Hua J; Hsieh MC; Zhou J; Petti G; Li X; Janjua A; Mendez M; Liu J; Longley C; Zhang Z; Mehlig M; Borowski V; Viswanathan M; Filpula D
Bioconjug Chem; 2006; 17(3):618-30. PubMed ID: 16704199
[TBL] [Abstract][Full Text] [Related]
2. N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.
Baker DP; Lin EY; Lin K; Pellegrini M; Petter RC; Chen LL; Arduini RM; Brickelmaier M; Wen D; Hess DM; Chen L; Grant D; Whitty A; Gill A; Lindner DJ; Pepinsky RB
Bioconjug Chem; 2006; 17(1):179-88. PubMed ID: 16417267
[TBL] [Abstract][Full Text] [Related]
3. Engineering an arginine catabolizing bioconjugate: Biochemical and pharmacological characterization of PEGylated derivatives of arginine deiminase from Mycoplasma arthritidis.
Wang M; Basu A; Palm T; Hua J; Youngster S; Hwang L; Liu HC; Li X; Peng P; Zhang Y; Zhao H; Zhang Z; Longley C; Mehlig M; Borowski V; Sai P; Viswanathan M; Jang E; Petti G; Liu S; Yang K; Filpula D
Bioconjug Chem; 2006; 17(6):1447-59. PubMed ID: 17105223
[TBL] [Abstract][Full Text] [Related]
4. Linear and branched bicin linkers for releasable PEGylation of macromolecules: controlled release in vivo and in vitro from mono- and multi-PEGylated proteins.
Zhao H; Yang K; Martinez A; Basu A; Chintala R; Liu HC; Janjua A; Wang M; Filpula D
Bioconjug Chem; 2006; 17(2):341-51. PubMed ID: 16536464
[TBL] [Abstract][Full Text] [Related]
5. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
Bell SJ; Fam CM; Chlipala EA; Carlson SJ; Lee JI; Rosendahl MS; Doherty DH; Cox GN
Bioconjug Chem; 2008 Jan; 19(1):299-305. PubMed ID: 18020402
[TBL] [Abstract][Full Text] [Related]
6. Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge.
Balan S; Choi JW; Godwin A; Teo I; Laborde CM; Heidelberger S; Zloh M; Shaunak S; Brocchini S
Bioconjug Chem; 2007; 18(1):61-76. PubMed ID: 17226958
[TBL] [Abstract][Full Text] [Related]
7. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity.
Pepinsky RB; LePage DJ; Gill A; Chakraborty A; Vaidyanathan S; Green M; Baker DP; Whalley E; Hochman PS; Martin P
J Pharmacol Exp Ther; 2001 Jun; 297(3):1059-66. PubMed ID: 11356929
[TBL] [Abstract][Full Text] [Related]
8. Site-specific PEGylation of bone morphogenetic protein-2 cysteine analogues.
Hu J; Duppatla V; Harth S; Schmitz W; Sebald W
Bioconjug Chem; 2010 Oct; 21(10):1762-72. PubMed ID: 20886828
[TBL] [Abstract][Full Text] [Related]
9. Expression, purification, and characterization of rat interferon-beta, and preparation of an N-terminally PEGylated form with improved pharmacokinetic parameters.
Arduini RM; Li Z; Rapoza A; Gronke R; Hess DM; Wen D; Miatkowski K; Coots C; Kaffashan A; Viseux N; Delaney J; Domon B; Young CN; Boynton R; Chen LL; Chen L; Betzenhauser M; Miller S; Gill A; Pepinsky RB; Hochman PS; Baker DP
Protein Expr Purif; 2004 Apr; 34(2):229-42. PubMed ID: 15003256
[TBL] [Abstract][Full Text] [Related]
10. Comparison of site-specific PEGylations of the N-terminus of interferon beta-1b: selectivity, efficiency, and in vivo/vitro activity.
Zhou Z; Zhang J; Sun L; Ma G; Su Z
Bioconjug Chem; 2014 Jan; 25(1):138-46. PubMed ID: 24341722
[TBL] [Abstract][Full Text] [Related]
11. Development of copper-catalyzed azide-alkyne cycloaddition for increased in vivo efficacy of interferon β-1b by site-specific PEGylation.
Nairn NW; Shanebeck KD; Wang A; Graddis TJ; VanBrunt MP; Thornton KC; Grabstein K
Bioconjug Chem; 2012 Oct; 23(10):2087-97. PubMed ID: 22988919
[TBL] [Abstract][Full Text] [Related]
12. PEGylation of proteins in organic solution: a case study for interferon beta-1b.
Peng F; Wang Y; Sun L; Liu Y; Hu T; Zhang G; Ma G; Su Z
Bioconjug Chem; 2012 Sep; 23(9):1812-20. PubMed ID: 22873735
[TBL] [Abstract][Full Text] [Related]
13. Solid-phase N-terminus PEGylation of recombinant human fibroblast growth factor 2 on heparin-sepharose column.
Huang Z; Ye C; Liu Z; Wang X; Chen H; Liu Y; Tang L; Zhao H; Wang J; Feng W; Li X
Bioconjug Chem; 2012 Apr; 23(4):740-50. PubMed ID: 22433083
[TBL] [Abstract][Full Text] [Related]
14. Site-specific PEGylation enhances the pharmacokinetic properties and antitumor activity of interferon beta-1b.
Lee JI; Eisenberg SP; Rosendahl MS; Chlipala EA; Brown JD; Doherty DH; Cox GN
J Interferon Cytokine Res; 2013 Dec; 33(12):769-77. PubMed ID: 23962003
[TBL] [Abstract][Full Text] [Related]
15. Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity.
Yamamoto Y; Tsutsumi Y; Yoshioka Y; Nishibata T; Kobayashi K; Okamoto T; Mukai Y; Shimizu T; Nakagawa S; Nagata S; Mayumi T
Nat Biotechnol; 2003 May; 21(5):546-52. PubMed ID: 12665803
[TBL] [Abstract][Full Text] [Related]
16. Pegylated peptides. IV. Enhanced biological activity of site-directed pegylated GRF analogs.
Felix AM; Lu YA; Campbell RM
Int J Pept Protein Res; 1995; 46(3-4):253-64. PubMed ID: 8537179
[TBL] [Abstract][Full Text] [Related]
17. Optimal site-specific PEGylation of mutant TNF-alpha improves its antitumor potency.
Yoshioka Y; Tsutsumi Y; Ikemizu S; Yamamoto Y; Shibata H; Nishibata T; Mukai Y; Okamoto T; Taniai M; Kawamura M; Abe Y; Nakagawa S; Nagata S; Yamagata Y; Mayumi T
Biochem Biophys Res Commun; 2004 Mar; 315(4):808-14. PubMed ID: 14985084
[TBL] [Abstract][Full Text] [Related]
18. Chemical modification of recombinant human keratinocyte growth factor 2 with polyethylene glycol improves biostability and reduces animal immunogenicity.
Huang Z; Ni C; Chu Y; Wang S; Yang S; Wu X; Wang X; Li X; Feng W; Lin S
J Biotechnol; 2009 Jul; 142(3-4):242-9. PubMed ID: 19477206
[TBL] [Abstract][Full Text] [Related]
19. Development of poly(ethylene glycol) conjugated lactoferrin for oral administration.
Nojima Y; Suzuki Y; Iguchi K; Shiga T; Iwata A; Fujimoto T; Yoshida K; Shimizu H; Takeuchi T; Sato A
Bioconjug Chem; 2008 Nov; 19(11):2253-9. PubMed ID: 18834167
[TBL] [Abstract][Full Text] [Related]
20. Enhanced circulation half-life of site-specific PEGylated rhG-CSF: optimization of PEG molecular weight.
Zhai Y; Zhao Y; Lei J; Su Z; Ma G
J Biotechnol; 2009 Jul; 142(3-4):259-66. PubMed ID: 19497340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
